{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-24-000014","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.947356+00:00","generated_at":"2026-06-04T19:39:51.628283+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"vTv Therapeutics elects Anne Phillips as director; Fry and Weiner resign","bullets":["Anne Phillips elected director effective March 13, 2024; will chair Compensation Committee and serve on Audit Committee.","John Fry and Howard Weiner resigned as directors effective upon filing of the 2023 Annual Report on March 13, 2024.","Ms. Phillips is independent under Nasdaq rules and will enter standard indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-24-000014","json":"https://secwatch.observer/filing/0001641489-24-000014.json","markdown":"https://secwatch.observer/filing/0001641489-24-000014.md","text":"https://secwatch.observer/filing/0001641489-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000014/0001641489-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000014/vtvt-20240313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:39:51.628283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03ceb542d5","claim":"Anne Phillips was elected as director at vTv Therapeutics Inc..","evidence_excerpt":"On March 12, 2024, Anne Phillips was elected as director of vTv Therapeutics, Inc. (the “Company”), effective and contingent on the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which occurred on March 13, 2024 (the “2023 Annual Report”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000014/0001641489-24-000014-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"ac5e80970f","claim":"Howard Weiner resigned as director at vTv Therapeutics Inc..","evidence_excerpt":"John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000014/0001641489-24-000014-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"dd57411c9f","claim":"John Fry resigned as director at vTv Therapeutics Inc..","evidence_excerpt":"John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000014/0001641489-24-000014-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}